NCT05642650Not yet recruiting
Novel Wearable Device for Heart Failure Management
Clinical Translational Research of Novel Wearable Device Based on Patented Sensing Technology in Non-Invasive Management of Heart Failure
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
Heart failure (HF) is a major cardiovascular disease with high readmission and mortality rate. A wearable device that could remotely monitor and detect the worsening HF early before the symptoms appear will help reduce HF readmissions effectively. The purpose of the current study is to examine the efficiency of a novel wearable device based on flexible strain sensor comparing to the clinical 'gold standard,' and then transform it into a clinical application.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- First submitted
- 15 Nov 2022
- Start date
- 28 Apr 2027
- Primary completion date
- 28 Apr 2029
- Lead sponsor
- China-Japan Friendship Hospital
- Diseases
- Heart failure
- NCT number
- NCT05642650
What you commit to
- Study type: Interventional
- Planned participants: 108
- From 28 Apr 2027 to the primary completion date, 28 Apr 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with severe arrhythmia.
- Subjects with cardiac shock.
- Subjects with acute myocardial infarction.
- Subjects with local skin infections and injuries in the jugular vein area
- Subjects with active uncontrolled infections
Lab values
- Subjects with eGFR \< 25 mL/min/1.73m2
Other
- Subjects unable to cooperate to complete the trial.
- Pregnant women, or women likely to undergo pregnancy
- Subjects with life expectancy less than 6 months
Who the study is looking for
- Diagnosis of HF ≥ 3 months
- Diagnosis of NYHA Class III HF
- Subjects with age ≥ 18 years
- At least 1 HF hospitalization within 12 months prior to enrollment
- Subjects with elevated ambulatory levels of BNP/NT-proBNP
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.